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http://www.parasitesandvectors.com/content/7/1/472RESEARCH Open AccessA murine macrofilaricide pre-clinical screening
model for onchocerciasis and lymphatic filariasis
Alice Halliday1, Ana F Guimaraes1, Hayley E Tyrer1, Haelly Mejane Metuge2, Chounna Ndongmo Winston Patrick2,3,
Kengne-Ouafo Jonas Arnaud2,3, Tayong Dizzle Bita Kwenti2,3, George Forsbrook1, Andrew Steven1, Darren Cook1,
Peter Enyong2, Samuel Wanji2,3, Mark J Taylor1 and Joseph D Turner1*Abstract
Background: New drugs effective against adult filariae (macrofilaricides) would accelerate the elimination of
lymphatic filariasis and onchocerciasis. Anti-Onchocerca drug development is hampered by the lack of a facile
model. We postulated that SCID mice could be developed as a fmacrofilaricide screening model.
Methods: The filaricides: albendazole (ABZ), diethylcarbamazine (DEC), flubendazole (FBZ), ivermectin (IVM) and the
anti-Wolbachia macrofilaricide, minocycline (MIN) were tested in Brugia malayi (Bm)-parasitized BALB/c SCID mice vs
vehicle control (VC). Responses were compared to BALB/c wild type (WT). Onchocerca ochengi male worms or
onchocercomata were surgically implanted into BALB/c SCID, CB.17 SCID, BALB/c WT mice or Meriones gerbils. Survival
was evaluated at 7–15 days. BALB/c SCID were tested to evaluate the responsiveness of pre-clinical macrofilaricides FBZ
and rifapentine (RIFAP) against male Onchocerca.
Results: WT and SCID responded with >95% efficacy following ABZ or DEC treatments against Bm larvae (P < 0.0001).
IVM was partially filaricidal against Bm larvae in WT and SCID (WT; 39.8%, P = 0.0356 and SCID; 56.7%, P = 0.026). SCID
responded similarly to WT following IVM treatment of microfilaraemias (WT; 79%, P = 0.0194. SCID; 76%, P = 0.0473). FBZ
induced a total macrofilaricidal response against adult Bm in WT and SCID (WT; P = 0.0067, SCID; P = 0.0071). MIN
induced a >90% reduction in Bm Wolbachia burdens (P < 0.0001) and a blockade of microfilarial release (P = 0.0215) in
SCID. Male Onchocerca survival was significantly higher in SCID vs WT mice, but not gerbils, after +15 days (60% vs 22% vs
39% P = 0.0475). Onchocercoma implants had engrafted into host tissues, with evidence of neovascularisation, after +7
days and yielded viable macro/microfilariae ex vivo. FBZ induced a macrofilaricidal effect in Onchocerca male implanted
SCID at +5 weeks (FBZ; 1.67% vs VC; 43.81%, P = 0.0089). Wolbachia loads within male Onchocerca were reduced by 99%
in implanted SCID receiving RIFAP for +2 weeks.
Conclusions: We have developed a ‘pan-filarial’ small animal research model that is sufficiently robust, with adequate
capacity and throughput, to screen existing and future pre-clinical candidate macrofilaricides. Pilot data suggests a murine
onchocercoma xenograft model is achievable.
Keywords: Anti-filarial, Lymphatic filariasis, Onchocerciasis, Macrofilaricide, Brugia, Onchocerca, WolbachiaBackground
The tissue dwelling filaria, Onchocerca volvulus, infects an
estimated 37 million people, predominantly in Sub-
Saharan Africa [1]. Ocular onchocerciasis (river blindness)
is the second leading cause of worldwide preventable
blindness [2] and is a priority neglected tropical disease
(NTD) targeted for elimination [3]. Current treatments* Correspondence: joseph.turner@lstmed.ac.uk
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unless otherwise stated.with ivermectin (IVM) target the transmissive stages of
O. volvulus, microfilariae (mf), in the skin, with limited ef-
ficacy against adult (macrofilariae) fertility or survival [4].
Whilst effective at reducing disease, due to repopulation
of the skin with mf post-treatment, IVM has to be admin-
istered periodically. In addition, IVM has to be delivered
for protracted periods (17-20+ years) due to the longevity
of macrofilarial infections (10–15 years). This presents a
challenge in sustainability with high population coverage
in mass drug administration programmes (MDA) tol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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mission cycle. Further, the emergence of sub-optimal
responders to IVM following repetitive treatments [5] and
the risk of severe adverse reactions in patients co-infected
with the bloodborne filaria, Loa loa [6], exert additional
challenges on maintaining control of onchocerciasis.
Drugs effective at killing adult Onchocerca (macrofilari-
cides), would be desirable to address this pressing global
health problem and accelerate the ultimate elimination of
onchocerciasis. New macrofilaricides may well also have
useful indications against the causative agents of lymphatic
filariasis; LF (Wuchereria bancrofti, Brugia malayi,
B. timori), especially to reduce the long tail of ‘endgame
mop-up’ in countries that have completed extensive
elimination programmes or in ‘hard to reach’ areas [1].
Existing Onchocerca macrofilaricides have either too low
selective toxicity (suramin) [7], are known to induce severe
adverse reactions contraindicating usage at doses required
to be effective (e.g. diethylcarbamazine or high dose iver-
mectin) [8,9] or presently cannot be delivered orally (e.g.
flubendazole) [10]. Whilst targeting the O. volvulus endo-
symbiont, Wolbachia, with tetracycline antibiotics has
proven safe in delivering macrofilaricidal activity, includ-
ing in individuals co-infected with L. loa [11,12], present
protracted treatment lengths (4–6 weeks) and contraindi-
cations in certain population groups (pregnant women
and children <8 years old) precludes the wide-scale use of
this class of anti-Wolbachia drug in large scale MDA [1].
Stimulated by renewed philanthropic investment by a
number of stakeholders, a number of drug discovery and
development programmes have been initiated to identify
new candidate macrofilaricidal therapeutics that can
effectively and safely target the macrofilarial stage of O.
volvulus or its endosymbiont in a timeframe compatible
with MDA delivery (generally considered an orally adminis-
tered course not exceeding seven days).
The development of Onchocerca macrofilaricides is
hindered by the lack of an appropriate small animal
laboratory model to robustly evaluate candidates in vivo
at the pre-clinical stage. A long term model of brugian
lymphatic filariasis (B. malayi/B. pahangi) is available in
the susceptible gerbil host Meriones unguiculatus [13]
and certain strains of inbred mice are susceptible to the
filaria, Litomosoides sigmodontis [14]. Whilst these ro-
dent filariasis models are undoubtedly useful in identify-
ing efficacious filaricidal compounds, overt differences in
the biology of Onchocerca species requires confirmation
of effectiveness at the pre-clinical stage before informed
decisions can be made about clinical development for
onchocerciasis indications. A current example of this
has been the lack of translation of macrofilaricidal
activity of the macrocyclic lactone, moxidectin, from
pre-clinical testing against Brugia in gerbils and dogs,
when evaluated by a phase II clinical trial in onchocerciasispatients [15,16]. Traditionally, the use of cattle naturally
infected with bovine Onchocerca (O. dukei, O. gutterosa,
O. ochengi, O. lienalis) has been exploited as a pre-clinical
system to scrutinise Onchocerca-specific macrofilaricidal
activity. Throughput is severely restricted by the logistics of
identifying and experimenting on parasitized cattle in sub-
Saharan Africa and the large quantities of drug required
to dose up to 0.5 metric tonne animals. Further, without
challenging empirical pharmacological evaluation, re-
quiring robust sample sizes, atypical pharmacokinetic
profiles within ruminants may lead to erroneous con-
clusions regarding efficacy.
A potential solution to the current challenges facing
pre-clinical onchocerciasis macrofilaricide evaluation is
the development of a small animal model of macrofilarial
onchocerciasis. Presently, only larval Onchocerca life cycle
stages are routinely used to screen filaricidal drug candi-
dates in mice. Infectious stage (L3) larvae of O. volvulus
can be implanted within micro-chambers to achieve only
abbreviated development to the L4 larval stage [17].
Microfilarial infections of the skin, utilising purified cattle
Onchocerca mf, can be established in inbred laboratory
mouse strains and have been utilised in pre-clinical filarici-
dal testing [18]. However, no reliable macrofilarial Oncho-
cerca small animal model has been described. Previous
attempts to utilize inbred mouse strains, including lym-
phopenic strains, to establish Onchocerca macrofilarial in-
fections from infectious stage (L3) larval inoculations, has
thus far proven unsuccessful [19]. However, Rajan and col-
leagues demonstrated that O. volvulus female worm ‘loops’,
exposed from surrounding nodular encasement in excised
nodules, could remain viable following implantation into
Severe-Combined ImmunoDeficiency (SCID) mice [20].
The same laboratory has also demonstrated that full devel-
opment of Brugia can occur in SCID strains [21]. Further,
our laboratory has previously demonstrated that O. lienalis
mf infections can persist for at least 100 days in SCID
recipients without waning [22].
Thus, in this paper, we evaluated the suitability of the
SCID mouse as a pre-clinical model to test macroflarici-
dal activity against filariae, using laboratory maintained
Brugia malayi to assess responsiveness to a range of
filaricidal compounds before trialling survival and drug
responses against Onchocerca ochengi implants.
Methods
Animals
Male BALB/c SCID were purchased from Harlan La-
boratories, UK, while male CB.17 SCID mice and BALB/c
WT mice were purchased from Charles River, UK. Male
Meriones unguiculatus (Mongolian gerbils; jirds) were
purchased from either Charles River, UK or Janvier La-
boratories, France. Rodents shipped to REFOTDE, Buea,
Cameroon, were maintained in conventional housing with
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bedding were sterilised by autoclaving. For B. malayi
experiments, animals were kept at the Biomedical Services
Unit (BSU), University of Liverpool, UK in specific
pathogen-free (SPF) conditions. All experiments carried
out in Cameroon were approved by the Animal Care
Committee, REFOTDE. All experiments on animals in
the UK were approved by the ethical committees of the
University of Liverpool and LSTM, and were conducted
according to Home Office (UK) requirements.
Brugia malayi parasites
The life cycle of B. malayi (Bm) was maintained in
mosquitoes and susceptible Meriones gerbils at LSTM.
To generate infective Bm larvae (BmL3) for infections,
female adult Aedes aegypti mosquitoes were fed with Bm
microfilariae (mf) collected from infected gerbils by
catheterisation, as previously described [23], followed by
mixing with human blood and feeding through an artifi-
cial membrane feeder (Hemotek®). Blood-fed mosquitoes
were reared for 14 days to allow for development to L3.
The L3 were collected from infected mosquitoes by
crushing and concentration using a Baermann’s appar-
atus and RPMI medium.
Onchocerca ochengi parasites
O. ochengi nodules were obtained from the skins of nat-
urally infected zebu cattle from the Adamawa region of
Cameroon through existing commercial practice for meat
production. At abbatoirs in the South West Province,
Cameroon, female cattle were checked for O. ochengi infec-
tion by palpation of the skin of the umbilical region for
onchocercomata. Positive skins were collected after slaugh-
ter. The tissue was then transported to REFOTDE, Buea
within 2 hours of collection. Skins were washed several
times and the hair was removed by shaving. Onchocerco-
mata were excised from dermal tissue using sterile scalpels
and forceps, and were placed in RPMI containing penicillin,
streptomycin and neomycin (RPMI + PSN). To obtain free
adult males, onchocercomata were cut gently to expose the
adult worms using sterile scalpels and were incubated in
petri dishes containing RPMI + PSN for 4 hours at 37°C,
5% CO2, to allow males to escape into the medium. Free,
intact and motile adult males were confirmed by visualisa-
tion of posterior anatomy, were washed several times in
fresh RPMI + PSN and kept at 37°C, 5% CO2 overnight.
B. malayi experimental infections
For B. malayi (Bm) L3 infection, 100 freshly collected,
motile Bm L3 were injected via the intra-peritoneal route.
Efficiencies of inoculations were confirmed by needle
washout. For mf perfusion, Bm mf were harvested by peri-
toneal washings of patently infected Meriones gerbils
under isoflurane anaesthesia, washed in RMPI + PSN andpurified by PD10 column size exclusion chromatography
(Amersham). Bm mf were enumerated by microscopy,
concentrated by centrifugation and 0.125 × 106 mf were
inoculated into the circulation via the lateral tail vein as
described previously [24].
Implantation of adult macrofilariae
Bm macrofilariae were collected from infected SCID mice
and were grouped into batches of 13 adults. Male BALB/c
SCID and BALB/c WT mice were placed under surgical
anaesthesia using isofluorane and were given s.c. injection
of bruprenorphine before 13 Bmmacrofilariae were placed
into the peritoneal cavity by making a small incision to the
skin and abdominal cavity wall in the upper right quad-
rant. The incisions were re-sutured after implant and
animals were individually housed after surgery.
For Onchocerca implants, rodents were placed under
surgical anaesthesia using i.p. injections of ketamine and
medetomidine. Onchocercomata were thoroughly cleaned
of bovine tissue, washed in several changes of RPMI +
PSN and small sections of the adult worms were exposed
by partial rupture of the capsule. Groups of 8–15 motile
O. ochengi male macrofilariae or 4 prepared O. ochengi
nodules were implanted into the peritoneal cavity or to
the cutaneous tissue of the upper side of the neck (for s.c
nodule implants). All wounds were re-sutured after
surgery and animals were individually housed and closely
monitored for the recovery period (7 days post-op).
Drug treatments
The drug doses in mg/kg and routes used in this study
were: Albendazole (ABZ; 50 mg/kg qd po), diethylcarbam-
azine (DEC; 50 mg/kg qd po), flubendazole (FBZ; 10 mg/
kg qd sc), ivermectin (IVM; 5 mg/kg qd ip or 15 mg/kg qd
po), minocycline (MIN; 25 mg/kg bid po) and rifapentine
(RIFAP; 15 mg/kg qd po). Drugs were dissolved in stand-
ard suspension vehicle (0.5% sodium carboxymethyl cellu-
lose; 0.5% benzyl alcohol; 0.4% Tween 80; 0.9% NaCl),
with the exception of MIN, which was dissolved in water,
RIFAP which was dissolved in 55% polyethylene glycol
300; 25% propylene glycol; 20% water and parenteral IVM
which was dissolved in 1% DMSO. Oral drugs were ad-
ministered in volumes of 100-200 μl by gavage. All drugs
were purchased from Sigma Aldrich.
Drug efficacy assessments
Developing larvae, macrofilariae and released mf were
recovered by peritoneal washings and enumerated by mi-
croscopy. Motile, unencapsulated worms were scored as
viable. Bm mf were centrifuged before being resuspended
in a known volume and a sample enumerated. For Bm mf
microfilaraemias, 30 μl thick films on uncoated glass slides
(Corning) were prepared from freshly-collected blood (tail
bleeds or cardiac punctures post-mortem) in 5000 U/ml
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were air dried, de-haemaglobinised in tap water, fixed in
80% MeOH and stained with Giemsa (BDH). Bm mf were
enumerated by microscopy. For recovery of O. ochengi
nodules, the nodule tissue was excised from the area of
tissue engraftment post-mortem. Nodules were dissected
and incubated in RPMI + PSN, 37°C, 5% CO2 for +4 h
before the presence of motile worms or mf was evaluated
by microscopy.
PCR quantification of Wolbachia
Individual adult filariae were fixed in RNAlater and
stored at 4°C. For Wolbachia enumerations, DNA was
extracted from worm samples using the DNeasy Blood
and Tissue Kit (Qiagen) according to manufacturer’s
instructions. Levels of Bm Wolbachia wsp and Bm gst
gene copy numbers were quantified using qPCR with
Bm-specific primers, as reported elsewhere [25]. Levels
of O. ochengi-specific wsp and gst were estimated using
identical PCR conditions, with the wsp primer pairs:
wsp420TGTTGGT(AG)TTGGT(GC)TTGGTG, wsp583
AACCAAA(AG)TAGCGAGC(CT)CCA and the gst pri-
mer pairs: gst175ATTGAAGCGCTTATTAGTCTGC, gst3
05TGTCGTTTCCATTTCATTTTC.
Statistical analysis
Where intra-group data was skewed, non-parametric
analyses were used to compare statistical differences
between two independent groups (Mann Whitney test)
or three or more independent groups (Kruskal Wallis
with Dunn’s post-hoc tests). Where intra-group data dis-
played a normal distribution, parametric 1way ANOVA
with Bonferroni post-hoc tests were used to examine
statistical differences between 3 or more groups. Paired
T tests evaluated changes in time within individual ani-
mals. Correlations were assessed for significance using
Pearson Correlation test. Significance is indicated by P <
0.05*, P < 0.01** and P < 0.001***.
Results
Evaluating the performance of reference filaricidal
compounds against B. malayi in SCID mice
We adapted mouse models of Brugian filariasis [26-28] to
scrutinise whether the standard anti-filarial drugs (SAFD)
albendazole (ABZ), diethylcarbamazine (DEC) and ivermec-
tin (IVM) or drugs with demonstrated macrofilaricidal
properties, flubendazole (FBZ) and the tetracycline anti-
wolbachia antibiotic, minocycline (MIN), displayed predict-
able efficacy in a Severe-Combined Immuno-Deficiency
(SCID) mouse model system.
For SAFD, which predominantly target the larval
stages of filariae in clinical and veterinary indications, we
inoculated either BALB/c SCID or BALB/c wild type
(WT) mice, as an immune-sufficient control, with 100infectious third stage (L3) of Brugia malayi (Bm) via the
intra-peritoneal route. Infected mice were orally admin-
istered with SAFD or vehicle control (VC) at indicated
doses for seven days, before Bm larvae were recovered
by peritoneal lavage (+24 h following the final drug
exposure) and motile parasites enumerated. Results are
shown in Figure 1. ABZ and DEC treatment delivered
an almost complete filaricidal activity in WT mice (100%
and >99%, respectively). These potent filaricidal effica-
cies were emulated within SCID hosts (ABZ; 98%, DEC;
100% reductions, P < 0.0001). IVM was partially filarici-
dal at the dose administered (15 mk/kg qd) in WT mice
(39.8% mean reduction, P = 0.0356). In SCID mice, a
partial filaricidal response was also evident (56.7% mean
reduction, P = 0.026).
To further assess responses of the SAFD, IVM,
against mf in the circulation, Bm mf were inoculated
via the tail vein into BALB/c SCID mice or BALB/c
immune competent controls. Initial parasitaemias were
measured at a baseline of +48 h after inoculation, be-
fore groups of mice were administered with a single
parenteral dose of 5MK IVM or VC. IVM induced rapid
reductions in microfilaraemia +24 h post-treatment
and levels further declined +7d post-treatment in both
WT and SCID mice (79%; P = 0.0194 and 76%; P =
0.0473 median reductions +7d, respectively, Figure 2A).
In SCID mice, the levels of mf recovered from the
cardiac puncture at termination were also significantly
reduced in IVM-treated mice (89% median reduction,
P = 0.0286, Figure 2B).
Whilst infectious stage Bm L3 are reported to
develop into mf-producing macrofilariae in SCID mice,
WT mice are refractory to full Bm development
[21,26]. For the purposes of validating direct FBZ macrofi-
laricidal efficacy in immunodeficient mice compared with
immunosufficient controls, we implanted a defined num-
ber of Bm macrofilariae sourced from +35 day ip infec-
tions of SCID donors into either WT or SCID recipients.
Following +2 day recovery from surgery, mice were
placed on parenteral FBZ suspension (10 mk/kg sub-
cutaneous, qd) or matching VC for a total of five days
and macrofilaricidal efficacy was evaluated +5 weeks
following the last drug exposure. Comparing VC
groups, there was a marginally non-significant de-
creased recovery of Bm macrofilariae in BALB/c WT
versus BALB/c SCID mice (P = 0.069). FBZ treatments
were 100% efficacious in both WT and SCID BALB/c
mice implanted with Bm macrofilariae (Figure 3A; aver-
age recovery of 0% FBZ treatment vs. 38%, P = 0.0067
for VC WT and 46% P = 0.0071 for VC SCID). En-
trapped immotile macrofilariae encapsulated within
leukocytic granulomas were frequently evident in WT
but not SCID mice (median recovery 4, WT vs 0, SCID,
P = 0.0104; Figure 3B).
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Figure 1 Comparative larvicidal activity of SAFDs against
Brugia in WT versus SCID mice. Percentage recoveries of BmL4
larvae from the peritoneal cavities of mice eight days after
inoculation with 100 BmL3 and commencement of a seven day oral
regimen of 50 mg/kg qd albendazole (ABZ), diethylcarbamazine
(DEC) or 15 mg/kg qd ivermectin (IVM). Circle plots are recoveries
from BALB/c WT mice whilst square plots are derived from BALB/c SCID
mice. Error bars are mean +/−SEM% recoveries per group. Data is pooled
from two individual experiments for WT and one experiment for SCID
mice (n = 4/group). Significant differences (1 way ANOVA with Bonferroni
multiple comparison) are indicated P < 0.001***, P < 0.01**, P < 0.05*.
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SCID mice to examine the response to oral treatment
with the anti-Wolbachia tetracycline, MIN, against the
macrofilarial stage of the parasite. SCID BALB/c mice
were infected with 100 infectious stage BmL3 larvae ip
and dosing with MIN or vehicle control (VC) com-
menced at +6wk post-infection, when parasites had
reached the juvenile adult stage. Mice were left for two
weeks following the last drug exposure and adult Bm
and released mf were collected at the early onset of
patency (+12wks post-infection). The average recovery of
adult Bm in control mice was 9.4 +/−2.6 SEM (n = 5) and
recoveries did not vary in MIN treated animals (Figure 4A).
Numbers of Wolbachia were quantified following DNA
extraction of individual female worms (n = 10/group,
pooled from individual mice; Figure 4B). In the control
group, average Wolbachia numbers per female were
5.865 × 107 +/−0.72 × 107. The average number of Wol-
bachia in female worms exposed to MIN in vivo in
SCID mice had been significantly reduced to 1.837 ×
106 +/−0.702 × 106. This equated to a 98.4% reduction
in Wolbachia (P < 0.0001). The majority of control mice
also contained peritoneal mf (4/5 mice; Figure 4C). Mf
production was enumerated per female worm and, on
average, each 12 week old female worm had produced373.3 (+/−204.4) mf. Contrastingly, there was a complete
absence of mf in the peritoneal cavity of MIN treated
SCID mice (P = 0.0215), consistent with loss of embryonic
development following the sterilisation of Wolbachia from
adult Bm filarial tissues.
Yields of Onchocerca macrofilariae from naturally
parasitized cattle
Zebu cattle, naturally infected with the bovine Oncho-
cerca species, O. ochengi, were identified within herds
moved from pasture land in the Adamawa Region and
slaughtered for meat production in abattoirs located in
the South West region of Cameroon. Over a 48-day col-
lection period, a total of 2612 nodules were collected from
28 infected hides (mean 105.5 +/− 28.4 SEM, Figure 5),
which were processed to purify motile male Onchocerca
macrofilariae. A positive correlation between numbers of
nodules recovered and numbers of adult males was ob-
served (Pearson R = 0.869; P < 0.0001) and, on average,
69.7 +/− 16.4 SEM motile male macrofilariae were recov-
ered per infected cattle hide processed. This was equiva-
lent to an average ratio of 0.66:1 male macrofilariae
recovered per harvested nodule.
Onchocerca macrofilariae survival following implantation
into WT/SCID mice and Mongolian gerbils
Using the intraperitoneal surgical implant technique as
detailed above for Bm, we implanted isolated motile
male Onchocerca macrofilariae into various laboratory
rodent models and evaluated survival following +15 days
(Figure 6). As well as comparison of WT vs SCID mice,
we tested survival in Mongolian gerbils (Meriones ungui-
culatus), an outbred laboratory rodent susceptible to a
number of other filariae. After 15 days post-surgical im-
plant, we successfully recovered parasites from all rodent
recipients with the exception of one WT BALB/c mouse.
Male Onchocerca macrofilariae recovered from rodent im-
plants were monitored for viability ex vivo in culture after
recovery from rodent hosts and motility comparable to
freshly isolated adult males was observable up to 7 days.
At +15 days, recoveries of male macrofilariae were, on
average, significantly lower in WT BALB/c versus SCID
BALB/c mice (22% vs 60% median recovery, P = 0.0475),
whilst the average recovery of Onchocerca male macrofi-
lariae was not significantly different in Meriones gerbils vs
WT or SCID BALB/c mice (38%).
We also trialled the implantation of isolated O.
ochengi onchocercomata, containing a mixture of cow
tissue plus both female and male Onchocerca macrofi-
lariae, into SCID BALB/c or SCID CB.17 strains. In
this pilot study, four onchocercomata were implanted
into the peritoneal cavity or sub-cutaneously at the
nape of the neck of each SCID recipient. Table 1 and
Figure 7 detail the parasitological observations +7 days
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Figure 2 Comparative microfilaricidal activity of IVM against Brugia in WT versus SCID mice. Bm mf densities in peripheral circulating
blood (A) or cardiac circulation (B) at ‘baseline’ (48 h following intravenous perfusion with 1.25 × 105 purified mf) or at indicated time points
following treatment with 5 mg/kg ivermectin (IVM) or vehicle control (VC) via the intraperitoneal route. Top panels are data derived from WT
BALB/c, bottom panels are data from BALB/c SCID mice. Error bars indicate median mf densities and interquartile range. Data is from an individual
experiment (n = 4/group). Significant differences with time (paired T Test) or between groups (Mann Whitney Test) are indicated *P < 0.05.
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http://www.parasitesandvectors.com/content/7/1/472following nodule implantation. At necropsy, the major-
ity of SCID BALB/c recipients (4/6) had evidence of
engraftment of some or all implanted onchocercomata
into abdominal visceral tissues, mainly connective tissues
continuous with the mesenteries and visceral fat pads. In
engrafted onchocercomata, neovacularisation could be
observed (9/24 implanted nodules), manifest as capillary
beds distributed across the capsule surface, stemming
from proximal host vascular networks. Onchocercomata
were extracted, partially dissected to expose loops of
female macrofilariae and cultured ex vivo for 4 hours. Ob-
servations of motility during this period revealed that in 5/
6 SCID recipients, 100% of implanted nodules contained
motile female Onchocerca macrofilariae. Transplantedonchocercomata yielded motile male Onchocerca
macrofilariae after recovery from 4/6 SCID recipients at
a ratio similar to that observed from freshly isolated
nodules (i.e. ~1 male/2 nodules). Following sub cutaneous
implantations in SCID CB.17 mice, 100% of onchocerco-
mata (n = 8) in 2/2 recipients displayed engraftment into
the sub cutaneous layer with evidence of neovascularisa-
tion. Vessel-like structures containing blood cells, prox-
imal to female worms, were identifiable within implanted
onchocercomata by histology. All onchocercomata recov-
ered from sub cutaneous implants at +7 days contained
motile female macrofilariae when dissected and cultured
ex vivo. A single motile male macrofilaria was released
from nodules derived from 1/2 recipient mice. Evidence of
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Figure 3 Comparative macrofilaricidal activity of FBZ against
Brugia in WT versus SCID mice. (A) % recoveries of Bm
macrofilariae and (B) numbers of granulomas recovered +6 weeks after
intraperitoneal surgical implantation into BALB/c WT or BALB/c SCID
mice and commencement of a 5 day 10 mg/kg qd sub-cutaneous
dosing with flubendazole (FBZ) or matching vehicle control (VC). Error
bars indicate median and interquartile range. Data is from an individual
experiment (n = 5/group). Significant differences between groups
(Mann Whitney Test) are indicated *P < 0.05, **P < 0.01.
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http://www.parasitesandvectors.com/content/7/1/472embryogenesis within implanted female Onchocerca uteri
was apparent by histological examination, including the
presence of inter-uterine stretched mf. Further, released
motile microfilariae were evident in the culture medium
following ex vivo culture of implanted sub cutaneous
onchocercomata derived from 2/2 SCID CB.17 recipients.
Evaluation of the SCID model of onchocerciasis as a
pre-clinical macrofilaricidal drug screen
Because of initial, reproducible, high recoveries of viable
male Onchocerca macrofilariae in BALB/c SCID mice,
we evaluated this model as an anti-Onchocerca in vivo
macrofilaricidal drug screen where survival over a more
protracted time frame (4–5 weeks) would be necessaryA B
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Figure 4 Anti-Wolbachia activity against Brugia macrofilariae in SCID
female Bm and (C) numbers of released mf per female Bm in BALB/c SCID mi
after commencement of 4 week oral 25 mg/kg bid minocycline (MIN) or vehi
Dashed horizontal lines in (B) indicate 1 and 2 log reductions compared with
Data is from an individual experiment (n = 5/group; individual worms pooled
are indicated *P < 0.05, ***P < 0.001.to evaluate macrofilaricide efficacy. We applied the opti-
mised FBZ screen verified in BALB/c SCID Bm implants
(Figure 3) to compare suitability of this system for
macrofilaricide testing. An increased number of 15 mo-
tile male Onchocerca macrofilariae were implanted into
each SCID mouse recipient to mitigate against decline in
survival over 5 weeks. Also, daily isolates of macrofilar-
iae (from individual cattle hides) were divided equally
between recipients consigned to FBZ or VC treatments
to avoid inter-group bias in quality and age of male
worms that might affect survival. Further, to mitigate
against inter-group variation in survival rates over a pro-
tracted period post-implantation masking macrofilaricidal
effects, group sizes were increased to 7–8 mice. Treatment
groups were maintained for up to 31 days (4–5 wks post
implant) before recovery of parasites (Figure 8). FBZ in-
duced a significant, almost total macrofilaricidal response,
with mean survival of 1.67% (+/−1.09, n = 8), compared
with a mean survival of 43.81% (+/−11.44, n = 7) recovery
in the VC group (P = 0.0089). In the treated group, single
motile worms were recovered in 2/8 recipients, whilst the
other six mice had either an absence of infection or recov-
ery of completely immotile worms. The two motile worms
derived from FBZ treated mice were moribund with
irregular and retarded ‘twitching’ motility, compared to
the motility rate observed of macrofilariae recovered from
VC mice or of freshly isolated onchocercomata.
We also tested a lead anti-Wolbachia rifamycin anti-
biotic, rifapentine (RIFAP), for activity against Onchocerca
male worms in CB.17 SCID mice. Groups of two mice
were given oral doses of RIFAP (15 mg/kg) or standard
suspension vehicle (VC) daily for 14 days, starting from
1–2 days recovery after surgery. Implanted Onchocerca
were retrieved +2 weeks after last drug exposure. Total re-
coveries of Onchocerca macrofilariae were not affected byC
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Figure 5 Yields of female and male Onchocerca macrofilariae isolated from naturally infected cattle. A) Typical yield of excised O. ochengi
onchocercomata from a parasitized cattle hide B) A pair of liberated, motile male O. ochengi worms +4 h after disruption of onchocercoma
(nodule) capsule and culture at 37°C/5%CO2. Scale bar =1 cm. C) Relationship between numbers of onchocercomata recovered per cattle hide
and number of motile male O. ochengi harvested. Dashed line is linear regression best fit. D) Recoveries of onchocercomata (closed plots) and
male O. ochengi (open plots) per cattle hide (n = 29). Error bars are mean +/− SEM.
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recovery, RIFAP; Figure 9A). Numbers of the single copy
Wolbachia surface protein (wsp) gene per isolated male
Onchocerca marofilariae were quantified as a surrogate
measurement of endosymbiont density within nematode
tissues (Figure 9B). A highly significant 99% reduction in
Wolbachia number was recorded in Onchocerca macrofi-
lariae obtained from CB.17 SCID mice treated with rifa-
pentine for 14 days (4.6 × 106 median wsp copies, VC vs.
0.0452 × 106, RIFAP, P < 0.001). Wolbachia reductions
were preserved when adjusted for potential variation in
size and age of adult male Onchocerca derived from cattle
onchocercomata, by normalisation to a single copy filarial
gene, gst (Figure 9C).
Discussion
The development of macrofilaricides against onchocer-
ciasis is currently hampered by a lack of a facile pre-
clinical infection model. Extrapolating efficacy of drug
candidates against lymphatic filariae in susceptible ro-
dents may not necessarily translate into effective oncho-
cerciasis indications and traditional pre-clinical testing
in cattle onchocerciasis does not possess the requiredthroughput to address current demand. For these rea-
sons we decided to develop and validate a small animal
model of onchocerciasis. We chose to trial SCID mice as
a compatible host for the cattle Onchocerca, O. ochengi.
We selected this particular parasite after identifying an
abundant and relatively convenient sampling source of
O. ochengi macrofilariae in cattle herds derived from the
Adamawa region of Northern Cameroon used for com-
mercial meat production. Our experience over a three-
month evaluation period indicated that the prevalence of
infected female cattle being moved for slaughter in the
South West Province was typically between 5-10% and
that, with around 10–20 cattle being processed daily at a
local abattoir, there was frequent availability of infected
cow tissues. Because we typically collected >100 O.
ochengi macrofilariae from a single hide, this provided an
adequate daily supply line of Onchocerca for in vivo drug
testing. The implantation of macrofilariae into groups of
rodents from a single cow effectively increased capacity
4–5 fold in terms of biological units available for drug
testing. Further, considering the much reduced space and
costs demanded for long-term husbandry of rodents vs
cattle, the rodent model should further facilitate increased
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Figure 6 Survival of male Onchocerca macrofilariae in
laboratory rodents. Percentage recoveries +15 days
post-intraperitoneal implantation with 8–12 isolated, motile male
Onchocerca macrofilariae in BALB/c WT, BALB/c SCID and Meriones
unguiculatus gerbils. Error bars are median recoveries with interquartile
range. For BALB/c SCID, data is pooled from two individual experiments
(n = 3/4). For BALB/c WT and Meriones, data is from a single experiment
(n = 3/4). Significant differences between groups (Kruskal-Wallis Test with
Dunn’s multiple comparison) is indicated *P < 0.05.
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http://www.parasitesandvectors.com/content/7/1/472capacity for simultaneous or overlapping Onchocerca drug
screening within the same laboratory, in a cost-effective
manner. The ability to culture the male O. ochengi macro-
filariae ex vivo for durations of at least five days, also
means that this method of collection could be applied to
in vitro testing of novel macrofilaricides, similar to the
published male O. gutterosa drug screen [29].Table 1 Parasitological observations of Onchocerca ochengi o
Mouse strain/ID Number/location Vascularisation
BALB/c SCID 1 4 ip 4/4
BALB/c SCID 2 4 ip 2/4
BALB/c SCID 3 4 ip 0/4
BALB/c SCID 4 4 ip 0/4
BALB/c SCID 5 4 ip 1/4
BALB/c SCID 6 4 ip 2/4
CB.17 SCID 1 4 sc 4/4
CB.17 SCID 2 4 sc 4/4
Intraperitoneal implantation (ip), sub cutaneous implantation (sc).
*motility assessed by dissection microscope +4 h after excision of nodule grafts, dis
nd – not done.The selection of SCID mice was based on extensive use
of this lymphopenic mouse system for xenograft transfers
in cancer and malaria chemotherapy pre-clinical testing
[30,31] and our own and other laboratory’s observations
that SCID mice are permissive hosts for non-murine fil-
ariae, including full development of the human lymphatic
filariae, B. malayi [21] and stage-specific Onchocerca spp.
infections [20,22].
A potential caveat to the application of SCID mice for
anti-filarial drug screening is the absence of adaptive im-
mune responses, which might be important in interacting
with candidate filaricidal compounds to induce macrofilar-
icidal effects. Whilst it is inconclusive whether inflamma-
tory reactions in patients post-treatment with anti-filarial
drugs (e.g. “Mazzoti reactions”) are a necessary compo-
nent in the death of filariae or merely a response to dead
and damaged worms [16] and the concomitant liberation
of somatic antigens and Wolbachia endobacteria [32,33],
the former has been proposed due to a general lack of effi-
cacy of SAFD at physiological levels in vitro against filariae
[34,35]. Further, various ‘immuno-pharmacological’ modes
of action have been proposed for SAFD, including the
prevention of immuno-modulatory secretions from mf by
IVM [36] and the induction of host inducible nitric oxide
and cyclooxygenase pathways by DEC [24]. Thus, it was
important to validate anti-filarial responses in the SCID
model against an immunologically intact WT control,
where possible. For this we took advantage of WT BALB/
c mice as an immune competent background strain that,
whilst resistant to chronic patent infections, accommo-
dates life cycle stages of B. malayi for periods sufficient to
evaluate filaricidal drug effects [24,27]. The results of our
studies, comparing larvicidal responses of the SAFD: ABZ,
DEC and IVM, illustrated no difference in the level of ob-
served efficacy of these reference anti-filarials against in-
fectious Bm L3 larvae, or in the case of IVM, bloodborne
mf, in the absence of adaptive immune responses. In fact,
for mf, we observed a 2.5 fold higher peripheral circulating
mf and 6.4 fold increased cardiac blood levels in SCID vsnchocercomata post-implantation into SCID mice
Motile females* Motile males* Motile mf*
4/4 2/4 nd
4/4 0/4 nd
4/4 0/4 nd
4/4 2/4 nd
0/4 2/4 nd
4/4 2/4 nd
2/2 0/2 yes
3/3 1/3 yes
ruption of nodule capsule and culture in complete medium at 37°C/5%CO2.
Figure 7 Engraftment of Onchocerca onchocercomata in SCID mice. Engrafted peritoneal (A&B) or sub cutaneous (C&D) onchocercomata
in situ or excised nodules from the peritoneum (D) or sub cutaneous tissue (E) +7 days after implantation into BALB/c or CB.17 SCID mice.
Haematoxylin and eosin staining of sub cutaneous engrafted onchocercomata illustrating embryogenesis (F) and putative murine host vessel-like
structures (H). High magnification images of inter-uterine stretched microfilarae (G) and vessel-like structure (I). Key: dermis (d), embryos (e),
visceral fat (f), mesentery (m), microfilariae (mf), nodule (n), female Onchocerca ochengi (o), uteris (u), vessel (v). Arrows indicate zones of
neovascularisation. Scale bars are 50 μm (F&H) and 10 μm (G&I).
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which allowed us to discern a more obvious treatment
effect of single dose IVM. We also observed similar mf
levels in CB.17 SCID mice (data not shown). The elevated
persistence of circulating mf in SCID mice may be due to
a lack of initiation of an effective stage-specific adaptive
immune response. Certainly, microfilariaemic brugian
filariasis patients have hyporesponsive filarial antigen-
specific peripheral blood mononuclear cell responses vs
amicrofilaraemic infected individuals [37]. Splenic clear-
ance has been demonstrable in controlling bloodborne
microfilaraemias in mice [38] and baboons [39] which
suggests that SCID mice may have a defective mechanism
at this secondary lymphoid organ.
This data extends experiments undertaken in athymic
nude mice that demonstrates a lack of a role for T lym-
phocytes/lymphocyte ‘help’ in a DEC mode of action [40]
and also suggests T and B lymphocyte-mediated adaptive
immunity is dispensable for the effects of the benzimid-
azole (BZ) and macrocyclic lactone families of anti-filarial
drugs. Further, a complete FBZ macrofilaricidal response
was apparent in both WT and SCID animals using a dose
regimen previously reported as effective in the Meriones
gerbil Brugia macrofilariae implant model [41]. FBZ
macrofilaricidal efficacy generally proceeded without overt
leukocytic granuloma formation in SCID mice suggesting
that these reactions are a response to dead worms but are
not integral to the mode of action of BZ anthelmintics.
Whether this extends to other classes of SAFD that have
macrofilaricidal activity against Bm, e.g. DEC and MOX,
remain to be evaluated.We extended our evaluation of the SCID mouse, tak-
ing advantage of the full development of Brugia in this
immunocompromised system, to assess the appropriate-
ness of its use as a facile anti-Wolbachia drug screen.
For this we chose a point of oral administration to drug
with the anti-Wolbachia reference tetracycline, MIN,
once parasites had undergone the final moult to become
immature macrofilariae. At this point in the Bm life
cycle, Wolbachia numbers have completed a log phase
expansion and are representative of levels in mature
Brugia (1-5 × 107 Wolbachia per female worm) [25]. Fur-
ther, initiating anti-Wolbachia drugging at the immature
macrofilarial stage allowed us to simultaneously and
rapidly discern downstream effects on embryogenesis via
initial mf release, at the immediate onset of patency
(+10-11 weeks in mice). We could consistently recover
Bm macrofilariae in infected and dosed SCID animals,
supporting prior observations of full permissiveness of
this model [21] and allowing for reliable production of
the required numbers of adult worms and mf release for
assessment of Wolbachia efficacy. Oral MIN administra-
tion in infected SCID mice for 28 days reduced Wolba-
chia loads within female Bm below the 90% threshold
deemed to irreversibly sterilise filarial tissues in clinical
studies, leading to macrofilaricidal effects [33,42,43].
The >90% levels of depletion observed in female macro-
filariae derived from drugged SCID Bm infections were
consistent with in vivo effects reported following pro-
tracted tetracycline treatments in patent Bm infections
of gerbils [44] and were reflected in a complete block-
ade in mf release in drugged animals.
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Figure 8 Macrofilaricidal activity of parenteral FBZ against
Onchocerca macrofilariae in SCID mice. Percentage recoveries
+5 weeks after intraperitoneal surgical implantation of 15 isolated,
motile male Onchocerca macrofilariae in BALB/c SCID mice and
commencement of a 5 day 10 mg/kg qd sub-cutaneous dosing
with flubendazole (FBZ) or matching vehicle control (VC). Error bars
indicate median and interquartile range. Data is from an individual
experiment (n = 7-8/group). Significant differences between groups
(Mann Whitney Test) are indicated **P < 0.01.
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Figure 9 Anti-Wolbachia activity against Onchocerca macrofilariae in
Onchocerca macrofilaria measured by wsp gene copy number or (C) Wolba
filarial gene copy number +29 days after intraperitoneal implantation in CB
15 mg/kg rifapentine (RIFAP) or vehicle control (VC). Error bars indicate me
log reductions compared with median VC levels. Median % reduction is ind
pooled from groups of two mice. Significant differences between groups (
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http://www.parasitesandvectors.com/content/7/1/472Having validated the SCID model system as suitably
responsive to a range of filaricidal reference compounds,
we tested survival rates of male Onchocerca macrofilariae
in either SCID BALB/c or WT BALB/c mice. The results
of a two-week implant pilot study indicated that male
Onchocerca survived significantly better in the immuno-
compromised system, suggesting that adaptive immune
responses begin to exert attritional effect on survival by
this stage. This is consistent with the kinetics of immune-
attrition against larval Bm infections where adaptive
immune responses begin to exert significant filaricidal
activity at +2 weeks post-infection [26]. We were also able
to preliminarily evaluate survival in the Brugia susceptible
outbred rodent, Meriones, which indicated that male
Onchocerca macrofilariae could persist at a similar level as
within SCID mice. As our focus was on development of a
flexible ‘pan-filarial’ SCID pre-clinical model, we did not
investigate survival in Meriones gerbils further. However
our initial findings suggest Meriones may also be a suitable
laboratory host for male Onchocerca implants and further
investigation is warranted to explore the length of persist-
ence in this immune-intact outbred rodent. It is debatable
whether macrofilaricides with a total reliance on adaptive
immunity would be suitable for indications in chronic fil-
ariasis patients who typically display hyporesponsive T cell
profiles to filarial antigens [37,45,46]. Furthermore, identi-
fication of ‘hits’ within in vitro culture screening assays
[29,47] would fail to identify drugs with a reliance on host
adaptive immune responses and as such, these candidates
would be suitable for in vivo evaluation in SCID mice.
However, should drugs emerge with putative T or B cell
adaptive immune-pharmacological mechanisms, the avail-
ability of comparative Bm and Onchocerca macrofilaricide
screens in WT mice, SCID mice and gerbils would serveC
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SCID mice. (A)% recoveries, (B) Wolbachia loads per motile male
chia loads per motile male Onchocerca macrofilaria as a ratio wsp/gst
.17 SCID mice and +28 days after commencement of 2 week oral
dian and interquartile range. Dashed horizontal lines indicate 1 and 2
icated in parentheses. For B&C, data from individual worms are
Mann Whitney Test) are indicated ***P < 0.001.
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of action and spectrum of anti-filarial effects.
By applying the efficacious FBZ regimen demonstrable to
exert macrofilaricidal effects against Bm adults, we could
reproduce the profound effect of this drug against im-
planted adult male Onchocerca macrofilariae within SCID
mice. This tallies with the reported macrofilaricidal effect of
the modified FBZ, UMF078, against O. ochengi in the nat-
ural cattle host [48]. Thus, our experiment demonstrates
‘proof of principle’ that the SCID mouse Onchocerca
macrofilariae implant model is sufficiently robust to test
macrofilaricide activity over a 5 week time frame. Because
single, moribund yet motile worms could be isolated in a
minority of FBZ treated mice, a slightly extended period
may be warranted to determine maximum macrofilaricidal
activity. Male macrofilariae were reproducibly recovered
from 100% of 22 SCID mouse recipients in our experi-
ments (discounting FBZ treatments), assessed between 2–5
weeks post implant (mean survival = 49.22% +/−5.08). It is
probable that more protracted durations of survival are
achievable and this requires further assessment.
Confirming our validation experiments with Bm, the
male Onchocerca macrofilariae SCID implant model was
also assessed as a suitable anti-Wolbachia screen, with
strong Wolbachia signal being reliably detected from indi-
vidual male Onchocerca worms and >98% depletions of
Wolbachia from filarial tissues recorded following ‘gold-
standard’ oral RIFAP treatment. This is consistent with
the rapid effects of the rifamycin class of antibiotics
observable in the B. malayi infection model in SCID mice
(manuscript in preparation).
The matching anatomical site of Bm adult parasitism
and Onchocerca macrofilariae implantation within the
peritoneal cavity of the pan-filarial SCID pre-clinical
screen, along with availability of both Brugia and Oncho-
cerca macrofilariae ex vivo screening systems, offers a
comprehensive suite of pre-clinical tools for robust in-
terrogation of novel macrofilaricide and anti-Wolbachia
drugs in development. This is further aided by a high
throughput cell screening assay for anti-Wolbachia drug
discovery [49]. The pan-filarial murine SCID host de-
scribed here will therefore provide a useful tool to facili-
tate the construction of rational PK/PD models and help
drive iterative medicinal chemistry to further improve
promising classes of drugs. Perhaps the most important
advance this model provides is the ability to more accur-
ately discern comparative drug class effects against differ-
ent genera of medically important filariae in a controlled
experimental system. Should the Bm life cycle be estab-
lished in sub-Saharan African laboratories, this raises the
possibility of undertaking dual Bm and Onchocerca
macrofilarial implants within the same host, which would
powerfully address the issue of drug effect on different
filarial genera.Given that SCID mice have an impaired mechanism of
foreign tissue rejection and are routinely used for grafting
human tumours [30] it was hypothesized that O. ochengi
onchocercomata from the dermis of infected cows could
survive upon engraftment into these mice, giving rise to
the possibility of developing a murine model containing
adult males, females and mf and keeping the natural ana-
tomical structure of the parasitic niche intact. This would
offer a desirable refinement to the male Onchocerca SCID
implant model and control for testing drug exposure
effects at a more naturalistic site of sub-cutaneous parasit-
ism and/or emulate drug targeting of worms within a
complex tissue surrounding of the onchocercoma. For this
reason we undertook a pilot study whereby onchocerco-
mata were implanted both into the peritoneal cavity and
sub-cutaneously. It was observed that, at both sites, many
of the nodules had become attached to host tissues and
the majority of nodules had evidence of rapid host neovas-
cularization. Vascularisation with both blood and lymph-
atic vessels is a consistent feature of O. volvulus nodule
microarchitecture [50-52]. Whether neovascularisation is
actively induced by pro-angiogenic parasite secretions [53]
or is part of an innate inflammatory response to foreign
material, remains to be resolved. Analogous to solid tu-
mours, that can be successfully targeted by antiangiogenic
therapies, neovascularisation is possibly a pre-requisite for
more protracted survival, as a source of nutrients and oxy-
gen supply deep within the nodule. Whilst only evaluated
for seven days, our pilot data is encouraging; 83% of the im-
planted nodules contained motile female macrofilariae and
25% also yielded motile male macrofilariae ex vivo. Whilst
no mf were observed from the culture of skin from the ear
or tail in SCID recipients of sub-cutaneous nodules, motile
mf were liberated after culturing recovered implants. This
suggests that female macrofilariae are fertile and produ-
cing mf post-implant in vivo. Because O. lienalis mf show
a cumulative increase in recruitment to the skin during
the first three weeks following inoculations in SCID mice
[22] extended experiments are required to determine the
dynamics of mf recruitment to the skin from implanted
nodules. As lymphatic growth into nodular tissue has been
proffered as an exit route for mf migration into the skin
[52], this process may be dependent on lymphangiogenic
responses developing within implanted nodules.
These experiments are ongoing and require further
optimization and refinement to test whether survival can
be achieved for longer periods in vivo, and thus whether
an onchocercoma xenograft (OX) model could also serve
as a platform for the screening of novel therapeutics. Rajan
et al. previously described that exposed ‘loops’ of O. volvu-
lus female worms embedded in onchocercomata could
remain viable and contain developing mf for up to 20 wks
post-implant in SCID mice [20], demonstrating the long-
term feasibility of this approach. We speculate that the
Halliday et al. Parasites & Vectors 2014, 7:472 Page 13 of 14
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ochengi vs. volvulus onchocercomata may facilitate an in-
crease in perfusion of host solutes, as well as our observa-
tions of neovascularization, to support protracted survival
of implanted female macrofilariae.
The full development of B. malayi and the protracted
survival of implanted O. ochengi in SCID mice raises the
possibility that this research model might be exploited
for drug screening against other medically important fil-
ariae. Recently, it has been demonstrated that L. loa can
develop to adulthood in immunodeficient mice (BALB/c
IL-4Rα−/−/IL-5−/−), although patent infections producing
circulating mf were not achieved [54]. Because the avail-
ability of a L. loa microfilaraemic mouse model would
supplement the identification of safe macrofilaricides
against onchocerciasis, an ongoing area of investigation
is the testing of L. loa development and survival within
inbred SCID mouse lines.
Conclusions
SCID mice can be successfully utilised to maintain all
life cycle stages of the lymphatic filariae, Brugia malayi
and adult stages of the cattle filaria, Onchocerca ochengi
with protracted survival. A range of reference anti-
filarial drugs including macrofilaricides targeting nema-
tode or Wolbachia endosymbionts have been tested
against Bm and O. ochengi in SCID mice. These refer-
ence drugs perform with matching efficacy compared
with either immune-competent controls or between the
two filarial genera. Thus, we have established a ‘pan-
filarial’ in vivo pre-clinical tool suitable to screen novel
macrofilaricides against both lymphatic and Onchocerca
filarial genera of medical importance.
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